EMIS - Development Update | NAVB Message Board Posts

Navidea Biopharmaceuticals, Inc.

  NAVB website

NAVB   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  30651 of 31047  at  9/20/2019 2:01:02 PM  by

RGIII


EMIS - Development Update

 

EMIS) proprietary Eligen® SNAC Carrier Technology.
" type="text" data-reactid="11">Some are asking about EMIS.....

 
ROSELAND, N.J., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Novo Nordisk announced today the Federal Food and Drug Administration (FDA) has approved Rybelsus, a semaglutide tablet, for the treatment of adults with type 2 diabetes.  Oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, utilizes Emisphere Technologies, Inc.'s ("Emisphere" or the "Company") (EMIS) proprietary Eligen® SNAC Carrier Technology.

https://www.novonordisk.com/media/news-details.2172050.html" type="text" data-reactid="12">A copy of Novo Nordisk's announcement can be found at
https://www.novonordisk.com/media/news-details.2172050.html

About Emisphere



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 237
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...